ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.226,82
-0,22%
S&P 500
5.308,15
1,17%
US Dollar vs BRL
5,1358
0,13%
Bitcoin
65.881,21
7,04%
Brent Oil
82,725
0,21%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. Canadá
  5. TSX
  6. Knight Therapeutics Inc (GUD)

  7. Knight Therapeutics Inc (GUD) Notícias

GUD

Knight Therapeutics (GUD)

Knight Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:TSX:GUD
DataHoraFonteTítuloCódigoCompanhia
10/08/202312:00AllPennyStocks.comTrading For This Specialty Pharma Company is up Following Second Quarter ResultsTSX:GUDKnight Therapeutics Inc
13/05/202110:38PR Newswire (Canada)L'OCRCVM permet la reprise de la négociation - GUDTSX:GUDKnight Therapeutics Inc
13/05/202110:37PR Newswire (Canada)IIROC Trade Resumption - GUDTSX:GUDKnight Therapeutics Inc
13/05/202109:25PR Newswire (Canada)Suspension de la négociation par l'OCRCVM - GUDTSX:GUDKnight Therapeutics Inc
13/05/202109:24PR Newswire (Canada)IIROC Trading Halt - GUDTSX:GUDKnight Therapeutics Inc
03/05/202107:00PR Newswire (Canada)Maverix Private Equity Announces Team AdditionsTSX:GUDKnight Therapeutics Inc
11/12/202019:15PR Newswire (Canada)S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite IndexTSX:GUDKnight Therapeutics Inc
11/12/202019:15PR Newswire (Canada)S&P Dow Jones Indices annonce des modifications à l'indice composé S&P/TSXTSX:GUDKnight Therapeutics Inc
08/01/202010:00PR Newswire (US)Knight Partners With Debiopharm for the Commercialization of Trelstar® in CanadaTSX:GUDKnight Therapeutics Inc
18/06/201918:00PR Newswire (US)Medimetriks Pharmaceuticals Focuses on Advancing MM36 (difamilast) Through Phase 3 Trials; Extinguishes Debt Owed to Knight T...TSX:GUDKnight Therapeutics Inc
29/04/201909:45PR Newswire (Canada)Medison Urges Fellow Shareholders to Bring Positive Change to Knight Therapeutics by Voting for All Six of Medison's Highly Q...TSX:GUDKnight Therapeutics Inc
25/04/201911:21PR Newswire (Canada)Leading Independent Proxy Advisory Firm ISS Recommends Change at Knight TherapeuticsTSX:GUDKnight Therapeutics Inc
18/04/201910:00PR Newswire (Canada)Medison Issues Presentation to Knight ShareholdersTSX:GUDKnight Therapeutics Inc
17/04/201908:00PR Newswire (Canada)Leading Canadian Corporate Governance Expert Confirms Acute Board Conflicts and Governance Deficiencies at Knight Therapeutic...TSX:GUDKnight Therapeutics Inc
16/04/201909:30PR Newswire (Canada)Medison Issues Letter to Shareholders of Knight Therapeutics, Outlining Qualified, Independent Director Nominees and Common-S...TSX:GUDKnight Therapeutics Inc
10/04/201909:39PR Newswire (Canada)Medison Disappointed that Knight Therapeutics has Resorted to Blatant Misrepresentations to Avoid ScrutinyTSX:GUDKnight Therapeutics Inc
08/04/201909:00PR Newswire (Canada)Medison Files Proxy Circular, Offers Knight Therapeutics Shareholders Truly Independent, Unconflicted Directors and Comprehen...TSX:GUDKnight Therapeutics Inc
01/04/201909:00PR Newswire (Canada)Medison to Nominate Six Highly Qualified Directors for Knight Therapeutics' Board to Strengthen Oversight and Drive Value Cre...TSX:GUDKnight Therapeutics Inc
18/02/201910:30PR Newswire (US)Knight Signs GUD (Bueno) Latin American Strategic Funding Deal with Moksha8TSX:GUDKnight Therapeutics Inc
19/03/201807:30PR Newswire (US)Ardelyx and Knight Collaborate to Bring Tenapanor to Patients in CanadaTSX:GUDKnight Therapeutics Inc
08/02/201812:21PR Newswire (US)60° Pharmaceuticals (60P) Receives Priority Review Designation For Malaria DrugTSX:GUDKnight Therapeutics Inc
04/01/201812:45PR Newswire (US)60 Degrees Pharmaceuticals Fast Tracked For Malaria DrugTSX:GUDKnight Therapeutics Inc
18/12/201712:00PR Newswire (US)60° Pharmaceuticals (60P) Submits New Drug Application to US FDA for Antimalarial Drug TafenoquineTSX:GUDKnight Therapeutics Inc
14/08/201718:30MarketwiredSynergy CHC Corp. Announces Second Quarter 2017 ResultsTSX:GUDKnight Therapeutics Inc
13/06/201709:03PR Newswire (Canada)Braeburn Pharmaceuticals and Knight Therapeutics Announce Filing of New Drug Submission for PROBUPHINE® in Canada for Opioid...TSX:GUDKnight Therapeutics Inc
09/12/201621:17PR Newswire (Canada)Indices S&P Dow Jones annonce des modifications à certains indices canadiens S&P/TSXTSX:GUDKnight Therapeutics Inc
22/03/201608:59PR Newswire (US)Profounda, Inc. launches Impavido® (miltefosine), the first and only oral Rx treatment for visceral, mucosal and cutaneous l...TSX:GUDKnight Therapeutics Inc
17/02/201611:54PR Newswire (US)Knight Breaks Glass on Medimetriks PartnershipTSX:GUDKnight Therapeutics Inc
01/02/201611:00PR Newswire (US)Braeburn Pharmaceuticals and Knight Therapeutics Announce Canadian Sublicense Agreement for PROBUPHINE®TSX:GUDKnight Therapeutics Inc
11/09/201518:15PR Newswire (Canada)S&P Dow Jones Indices Announces Changes to the S&P/TSX Canadian IndicesTSX:GUDKnight Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:TSX:GUD

Seu Histórico Recente

TIDE
MTLBTC
BIT
P1TL06
BNP Paribas Issuance
BIT
UC2A00
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados